Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

CS-917 fails to significantly lower placebo-adjusted HbA1c level in phase IIb study

July 20, 2007

Gruenenthal and Aventis sign licensing agreement for trimegestone

July 20, 2007

Affymax begins phase III trials of Hematide

July 20, 2007

Neuropeptide Y a therapeutic target for obesity

July 20, 2007

Update on Hollis-Eden's phase I trial of HE-3286 for type 2 diabetes

July 19, 2007

Centrix signs manufacturing and supply agreement with Cedar for Northyx

July 19, 2007

Manufacturing agreement signed for GMP production of hGH-CTP

July 19, 2007

RANKL: Target To Watch for development of therapeutics for treatment of osteolytic bone disorders

July 19, 2007

FDA approves initiation of phase III trials for Protalix's prGCD

July 18, 2007

Novel therapeutic options for obesity described in recent patent literature

July 18, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Roche secures CE mark for Alzheimer’s blood test
BioWorld
Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out amyloid pathology, a hallmark of...